Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (January 2021)
18 slides from Endra Life Sciences's investor presentation, Jan 11, 2021
Slide 1: Practical Assessment of Hepatic Steatosis for NAFLD-NASH
Practical Assessment of Hepatic Steatosis for NAFLD - NASH INVESTOR PRESENTATION JANUARY 2021 See more. Do more. Live better.® NASDAQ: NDRA
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements made in this presentation are forwardooking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding the timing of our cinical tras, our strategy, future operations, future financ
Slide 3: ENDRA Life Sciences' Goal
ENDRA Life Sciences’ Goal SEE MORE. DO MORE. LIVE BETTER. ° Commercialize Thermo Acoustic Enhanced UltraSound (TAEUS®), a technology that enhances existing ultrasound systems to visualize tissue similar to an MRI, but at 50X" lower cost and at the point of patient care. @EnoRA NASDAG: NORA
Slide 4: ENDRA Life Sciences
ENDRA Life Sciences = « @® PLATFORM TECHNOLOGY Opportunities in a variety of clinical applications Multiple potential revenue streams: hardware, software, services, disposables, licensing 78 IP assets’ (ENDRA 18* APPLICATION: LIVER DISEASE 1.4B people? affected by excess liver fat and inflammation ~
Slide 5: Large Unmet Clinical Need: NAFLD-NASH Diagnostics
Large Unmet Clinical Need: NAFLD-NASH Diagnostics RAMPANT DISEASE, APPROACHING THERAPIES ... BUT NO PRACTICAL DIAGNOSTIC TOOLS Liver Disease: NAFLD-NASH Diagnostic Gap 1st Therapies Near 1.4 billion people affected.’ No practical diagnostic tools: Advent of first targeted Linked to obesity, diabetes
Slide 6: Assessing & Monitoring Liver Fat of Billion NAFLD-NASH Patients
Assessing & Monitoring Liver Fat of 1 Billion* NAFLD-NASH Patients NO TOOL HAS BALANCED DIAGNOSTIC VALUE + ACCESSIBILITY HIGH LO (@enoRA DIAGNOSTIC VALUE = OPTIMAL BALANCE ) VALUE + ACCESSIBILITY Quantitative} Ultrasound Traditional Ultrasound Exe Medical Tests History & BMI LOW ACCESSIBILITY HGH (A
Slide 7: ENDRA's TAEUS: Enhancing Traditional Ultrasound
ENDRA’s TAEUS®: Enhancing Traditional Ultrasound RADIO FREQUENCY PULSES CREATE SONIC WAVES THAT QUANTITATE LIVER FAT FRACTION v TAEUS directly measures a material property of liver tissue that is only I affected by the amount of fat (triglyceride), and has not been found to be confounded by fibrosis
Slide 8: TAEUS Liver Commercialization: Core Elements
TAEUS Liver Commercialization: 3 Core Elements TARGET CLINICIANS @ LOCAL LEVEL ENDRA CRM 10 clinician names’ 7 RSNA DRIVE AWARENESS, INTEREST & TRIAL ~ i. ie I “easL BUILD CLINICAL EVIDENCE @vpmc ENDRA clinica luati each target market. mgt =e porting comm: ization. Germany France renee WWW.ENORAINC.
Slide 9: TAEUS Liver: Targeting High-Value Segments
TAEUS® Liver: Targeting High-Value Segments CLINICIANS & DRUG DEVELOPERS STRUGGLE WITH SAME MRI-BIOPSY LIMITATIONS IMAGING EXPERTS LIVER EXPERTS METABOLISM & DRUG DEVELOPERS Radiology Gastro-Hepatology LIFESTYLEEXPERTS += Pharma & CRO’s -100,000 - 45,000 -300,000 ~50 companies practitioners’ practit
Slide 10: TAEUS Platform Evolution
TAEUS® Platform Evolution: MULTIPLE POTENTIAL CLINICAL APPLICATIONS & REVENUE STREAMS TO SCALE BUSINESS HARDWARE SOFTWARE SERVICES DISPOSABLES LICENSING ‘TAEUS accessory TAEUS SW apps added to Eg, Maintenance Eg, Applicator pads —_Build-in TAEUS as increases utility of existing TAEUS accessory or co
Slide 11: Future TAEUS Application: Guidance of Energy-Based Surgery
Future TAEUS Application: Guidance of Energy-Based Surgery SHOW HEAT OR COLD SIGNATURE OF THERMO-ABLATIVE PROCEDURES FOR CANCER, CARDIOLOGY, PAIN THERMO-ABLATIVE PROCEDURES * 5* million procedures annually’ growing at 15%! CAGR, driven by aging-related diseases: cancer, pain, cardiology Temperature
Slide 12: Anticipated Milestones: ENDRA Liver Application
Anticipated Milestones: ENDRA Liver Application SECURE REGULATORY APPROVALS, RAMP COMMERCIALIZATION, BUILD CLINICAL EVIDENCE * Receive FDA 510{k) * Ramp commercialization in EU & US; first revenue from sale of TAEUS * Collect & publish TAEUS clinical evidence from global reference partners * Forge n
Slide 13: Financial Information
Financial Information KEY STATISTICS Dec 31, 2020 Pro-Format Cash Balance $7.3M Common Stock Price (NASDAG: NDRA) $0.75 Common Shares Outstanding 33.5M Fully Diluted Shares Outstanding 41.4M Market Capitalization $25.2M Management / Director Ownership? 10.7% 1 Pro forma reeuts for December 31, 2020
Slide 14: Contact Us Appendix
CONTACT US APPENDIX ENDRA LIFE SCIENCES David Wells Chief Financial Officer (734) 997-0464 Investors@endrainc.com www.endrainc.com See more. Do more. Live bette?
Slide 15: Leadership & Advisors
Leadership & Advisors MANAGEMENT Francois Michelon Chairman & CEO 20! years in med-tech GE Healthcare, Smith & Michael Thornton cro 15° years medtech Founder, Enhanced Nephew, Biomet Vision Systems (sold to GE) INDEPENDENT DIRECTORS Sam Gambhir, MD, PhD — Michael Harsh in Memoriam 1862-2020 Chief Te
Slide 16: Expected TAEUS Economic & Clinical Value To Stakeholders
Expected TAEUS Economic & Clinical Value To Stakeholders PATIENTS HEALTHCARE PROVIDERS PAYERS Ultrasound Procedure TAEUS Procedure Education & Reimbursement Clinician offers optional (patient setf- royce is wobceagel aatense (pay) TAEUS liver scan? for ~$35° 1. Giinician submissions of TAEUS follow
Slide 17: Liver Fat Measurement Tools: Relative Performance & Accessibility
Liver Fat Measurement Tools: Relative Performance & Accessibility Diagnostic Accessibility Liver Fat (Steatosis) Test AUROG* Sensitivity? Specificity? Value —_—[Atordatilty Other Considerations + Measuremert variabity de to pathology interpretation Liver Biopsy starical Gd Standard for NASH Diaqrsis
Slide 18: Sources & Assumptions
Sources & Assumptions PAGE 3 11 SOK ENORA device estimated price compared to $2.5M MFU price 1 haset fed. issued and Icenced patents and pending patent applications 2 Hepatotogy, The aconamic and cinic! arden of nana fatty her dcaase nthe United ‘States and Europe. Younoan. Bissett. Henry, Stspanova
ENDRA Life Sciences — Investor Presentation (January 2021) on 6ix